Ethyl 3-amino-5-(trifluoromethyl)benzofuran-2-carboxylate | 1228148-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: Ethyl 3-amino-5-(trifluoromethyl)benzofuran-2-carboxylate
• 英文别名: ethyl 3-amino-5-(trifluoromethyl)-1-benzofuran-2-carboxylate
• CAS: 1228148-42-2
• 化学式: C₁₂H₁₀F₃NO₃
• 分子量: 273.212
• InChiKey: ARBAHOBBJGUIJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Ethyl 3-amino-5-(trifluoromethyl)benzofuran-2-carboxylate 、 8-Chloro-3H-benzo[4,5]furo[3,2-d]pyrimidin-4-one 生成 8-Trifluoromethyl-3H-benzo[4,5]furo[3,2-d]pyrimidin-4-one
  参考文献：
  名称：

  Pyrimidine Compounds for the Treatment of Inflammatory Disorders

  摘要：

  本发明涉及新型嘧啶化合物，用于调节组胺H4受体并治疗或预防由组胺H4受体介导的疾病。该发明还涉及这种化合物的制备。

  公开号：

  US20080261946A1
• 作为产物：
  描述：

  Ethyl (2-cyano-4-trifluoromethylphenoxy)acetate 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 生成 Ethyl 3-amino-5-(trifluoromethyl)benzofuran-2-carboxylate
  参考文献：
  名称：

  Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists

  摘要：

  The identification and hit-to-lead exploration of a novel, potent and selective series of histamine H(4) receptor inverse agonists is described. The initial hit, 3A (IC(50) 19 nM) was identified by means of a ligand-based virtual screening approach. Subsequent medicinal chemistry exploration yielded 18I which possessed increased potency (R-enantiomer IC(50) 1 nM) as well as enhanced microsomal stability. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.097

文献信息

• PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：Cellzome (UK) Ltd.

  公开号：EP1945646A1

  公开（公告）日：2008-07-23
• [EN] PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE PYRIMIDINE POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：CELLZOME UK LTD

  公开号：WO2007039467A1

  公开（公告）日：2007-04-12

  [EN] The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.
  [FR] La présente invention concerne de nouveaux dérivés de pyrimidine pour la modulation du récepteur H4 de l'histamine et le traitement prophylactique ou thérapeutique d'états pathologiques faisant intervenir le récepteur H4 de l'histamine. La présente invention concerne en outre la synthèse de tels composés.
• Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists
  作者：Sue Cramp、Hazel J. Dyke、Christopher Higgs、David E. Clark、Matthew Gill、Pascal Savy、Neil Jennings、Steve Price、Peter M. Lockey、Dennis Norman、Soraya Porres、Francis Wilson、Alison Jones、Nigel Ramsden、Raffaella Mangano、Dan Leggate、Marie Andersson、Richard Hale

  DOI：10.1016/j.bmcl.2010.02.097

  日期：2010.4

  The identification and hit-to-lead exploration of a novel, potent and selective series of histamine H(4) receptor inverse agonists is described. The initial hit, 3A (IC(50) 19 nM) was identified by means of a ligand-based virtual screening approach. Subsequent medicinal chemistry exploration yielded 18I which possessed increased potency (R-enantiomer IC(50) 1 nM) as well as enhanced microsomal stability. (C) 2010 Elsevier Ltd. All rights reserved.
• Pyrimidine Compounds for the Treatment of Inflammatory Disorders
  申请人：Dyke Hazel

  公开号：US20080261946A1

  公开（公告）日：2008-10-23

  The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.

  本发明涉及新型嘧啶化合物，用于调节组胺H4受体并治疗或预防由组胺H4受体介导的疾病。该发明还涉及这种化合物的制备。